Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Phase 2 Active not recruiting 40 enrolled Washington University School of Medicine UConn Health · collab

NaSingle-groupOpen-labelPrevention

Summary

This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.

Timeline

Start: 2023-07-01
Primary completion: 2027-10-01
Completion: 2027-10-01

Publications

Schweiger A, Diniz B, Nicol G, Schweiger J, Dasklakis-Perez AE, Lenze EJ. Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders. F1000Res. 2025 Mar 5;13:1072. doi: 10.12688/f1000research.151963.2. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Quercetin	Small molecule	1250 mg	Oral
Subject	dasatinib anhydrous	Small molecule	100 mg	Oral

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Summary

Timeline

Publications

Drugs

Indications